#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Chronic kidney disease

Recruiting

Registered drug

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug

Sweden

Participants:18–64 years · 65+ years
Substances:Azd5004

Contact Research Centre

Cardiovascular disorder+2

Recruiting

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Sweden

Participants:18–64 years · 65+ years
Substances:Bi 690517

Contact Research Centre

Arteriosclerosis

Recruiting

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Sweden

Participants:18–64 years · 65+ years

Contact Research Centre

Arteriosclerosis

Recruiting

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Sweden

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide

Contact Research Centre

Acute myocardial infarction

Recruiting

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Sweden

Participants:18–64 years · 65+ years
Substances:Selatogrel

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Registered drug

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

Registered drug

Sweden

Participants:18–64 years · 65+ years
Substances:Tocilizumab

Contact Research Centre

Therapy cessation

Recruiting

Registered drugNo placebo

Study of the effects of stopping elranatamab and teclistamab treatment in patients with multiple myeloma who have had a significant response to therapy.

Registered drugNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:Elranatamab

Contact Research Centre

Vestibular disorder

Recruiting

Registered drug

A Study of Prednisolone Compared to Placebo for Patients with Vestibular Neuritis to Evaluate Effects on Balance and Dizziness Symptoms

Registered drug

Sweden

Participants:18–64 years · 65+ years
Substances:Prednisolone

Contact Research Centre

Multiple sclerosis

Recruiting

Registered drugNo placebo

Study of rituximab followed by cladribine for patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration

Registered drugNo placebo

Sweden

Participants:18–64 years
Substances:ACICLOVIR SODIUM

Contact Research Centre

Cervix carcinoma

Recruiting

Registered drugNo placebo

Study on HPV Vaccine and Screening to Reduce HPV Infection and Cervical Cancer in Swedish Women Aged 23-25

Registered drugNo placebo

Sweden

Participants:18–64 years · Healthy volunteers
Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Registered drugNo placebo

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:Obinutuzumab

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study on EGFR-Mutated Lung Cancer: Evaluating Dacomitinib, Afatinib, and Osimertinib for Patients Not Suitable for Curative Treatment

Registered drugNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:Afatinib

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.